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Abstract.
Background: Subjective cognitive decline (SCD) is associated with an increased risk of Alzheimer’s disease (AD). However,
patients reporting SCD to their general practitioner are not always referred to a memory clinic.
Objective: To investigate whether prior history of medical help-seeking is associated with AD biomarker abnormality, worse
cognitive performance, and/or depressive symptoms in SCD.
Methods: We compared levels of cerebrospinal fluid (CSF) A1-42, cognitive performance, and depressive symptoms (15-
item Geriatric Depression Scale, GDS-15) between healthy controls (n = 88), SCD with a history of medical help seeking
(SCD-HS, n = 67), and SCD non help-seekers (SCD-NHS, n = 44). Cases with evidence of amyloid plaques (CSF A1-42
≤708 ng/l) and symptoms of depression (GDS-15≥6) were determined in both SCD groups.
Results: The SCD-HS group had lower CSF A1-42 (p < 0.01), lower word list learning and memory recall (p < 0.0001), and
an increased level of depressive symptoms (p < 0.0001) compared to controls and SCD-NHS cases. The SCD-HS group had
more cases with symptoms of depression (n = 12, 18%) and amyloid plaques (n = 18, 27%) compared to SCD-NHS (n = 1,
2% and n = 7, 16%, respectively). None of the SCD-HS cases and only one SCD-NHS case had concurrent symptoms of
depression and amyloid plaques. The SCD-HS cases showed equal word list learning and memory performance regardless
of amyloid status or symptoms of depression.
Conclusion: Medical help-seeking in SCD is associated with an increased risk of AD pathology or symptoms of depression.
However, subtle memory deficits are seen in SCD help-seekers, also without amyloid plaques or symptoms of depression.
Keywords: Alzheimer’s disease, amyloid plaques, cerebrospinal fluid A1-42, cognitive symptoms, early diagnosis, help-
seeking behavior, medical help-seeking, neuropsychiatric symptoms, neuropsychological tests, subjective cognitive decline
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INTRODUCTION
Studies have shown that the pathophysiological
underpinnings of Alzheimer’s disease (AD) may
begin 10 to 15 years before the emergence of
detectable mild cognitive impairment (MCI) [1, 2].
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This extended preclinical phase constitutes a pos-
sible window for preventive interventions [1, 3].
Improved methods for earlier identification of AD in
the preclinical phase are therefore needed. Subjective
cognitive decline (SCD), the self-perceived decline
in cognitive functions while performing within the
normal range on cognitive tests, is associated with
an increased risk of MCI and dementia due to AD
[4–10]. Indeed, the presence of amyloid plaques,
a hallmark of AD, in cognitively healthy persons
with SCD has shown to predict later decline in
memory functions [11–13]. Moreover, SCD may be
accompanied by functional alterations in hippocam-
pal integrity reflecting compensatory mechanisms
that preserve memory performance [14].
However, SCD is heterogeneous, often a benign
condition, and most cases do not progress to dementia
[4, 5, 15–19]. A recent study found increased levels
of stress/depressive symptoms in SCD with a low
prevalence of altered CSF AD biomarkers over time,
suggesting that AD is not the most frequent etiology
[15]. At present, AD is assessed using cerebrospinal
fluid (CSF) or positron emission tomography (PET)
imaging analyses, procedures which are invasive or
costly. Thus, methods to improve the detection of
SCD cases with incipient AD are of value for the
selection of candidates eligible for early intervention
trials.
Recruitment of MCI and SCD participants through
memory clinics include individuals with higher rates
of abnormal CSF biomarkers and increased brain
amyloid- (A) deposition as compared to self-
referred participants from the community [20–23].
We and others have shown that MCI recruited through
memory clinics also have poorer cognitive func-
tion than community samples [21, 24, 25]. However,
while memory clinic SCD cases have shown higher
conversion rates to MCI compared to community
cases [23, 26], and lower baseline cognitive per-
formance in one study [27], most studies have not
found any baseline cognitive differences in SCD
cases due to recruitment source bias [22, 24, 26].
The biases observed from recruiting memory clinic
SCD cases may stem from worries or concerns felt by
either patients, or their families reaching a threshold
prompting the person to seek medical help. Indeed,
worried individuals with SCD have increased risk of
developing objective cognitive decline [6, 28, 29].
However, patients who report SCD to their general
practitioner (GP) may not be referred to a memory
clinic for assessment [30]. In a previous study, we
found no significant cognitive differences between
SCD cases recruited from memory clinics as com-
pared to SCD cases recruited from a community
sample [24].
In the present study, we hypothesize that SCD cases
with a history of medical help-seeking, independent
of recruitment source, carry a higher risk of AD com-
pared to non-help-seeking SCD cases and healthy
controls. We compare levels of CSF AD biomark-
ers (A1-42, total tau, and phosphorylated tau) and
cognitive performance between these groups. In addi-
tion, we investigate levels of depressive symptoms
between groups, as depressive symptoms may play
a role in the expression of SCD as well as medical
help-seeking. Lastly, we investigate the association
between pathological CSF A1-42 levels (e.g., the
presence of amyloid plaques) and frequencies of
cases with symptoms of depression (15-item Geri-
atric Depression Scale (GDS-15)≥6) [31], in both
help-seeking and non-help-seeking SCD cases.
METHODS
The present study is part of the Norwegian multi-
center study, Dementia Disease Initiation (DDI), a
collaboration between all Norwegian health regions
and University hospitals. Between January 2013 and
January 2019, participants with self-reported cog-
nitive decline and healthy controls were recruited.
The DDI cohort comprises self-referred participants
following advertisements in media, newspapers, or
news bulletins, and patients referred from their gen-
eral practitioners to local memory clinics. Healthy
controls were included from spouses of patients with
dementia/cognitive disorder, and from patients who
completed lumbar puncture for orthopedic surgery.
Classification of participants as either healthy con-
trols, SCD, MCI, or dementia were performed
according to published criteria [28, 32–34].
Inclusion criteria were a native language of Nor-
wegian, Swedish, or Danish and age between 40 and
80 years. Participants with a medical history of brain
trauma or brain disorder, including clinical stroke,
dementia, severe psychiatric disorder, severe somatic
disease that might influence cognitive functions, or
intellectual disability or other developmental disor-
ders were excluded. All participants were examined
with a case report form developed for DDI. The case
report form is administrated as a structured interview
and includes a standardized assessment protocol for
cognitive impairment and SCD (see below), medi-
cal history from participant and informant, physical
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and neurological examinations as well as the 15-item
version of the GDS [31]. All participants underwent
cognitive examination comprising the Mini-Mental
State Examination (MMSE-NR) [35], non-verbal
cognitive screening (The clock drawing test) [36],
verbal memory (CERAD word list) [37], visuoper-
ceptual ability (VOSP silhouettes) [38], psychomotor
speed and executive functions (Trail making (TMT)
A and B) [39], and word fluency (COWAT) [40]. For
further description of the DDI cohort and methods,
see Fladby et al. (2017) [20].
Classification of SCD and cognitively normal
healthy controls
Classification of subjects as either SCD or cog-
nitively normal healthy controls was performed as
part of a structured interview with standardized ques-
tions, the DDI case report form. It includes a broad
description of participants’ symptoms and experi-
ence of subjective cognitive decline according to the
suggested framework by the working group of SCD-
I. It considers onset of decline, cognitive domain,
patient concerns and worries, if feeling of being
worse compared to age-matched peers is present, and
when available, informant confirmation of decline.
Participants recruited from other sources than the
memory clinics were asked if they had previously
sought medical help due to SCD. Published norms
(adjusted for age, sex, and educational effects) for
the different tests were used to classify performance
as normal or abnormal [38, 41, 42]. We applied a
threshold of GDS-15 total score ≥6 [31] for symp-
tom of depression [31]. Cognitive performance was
deemed normal if the participant obtained normative
scores above T = 35 (≥1.5 SD) on either CERAD
word list (delayed recall), VOSP silhouettes, TMT-
B, or COWAT. Participants with normal cognitive
performance on standardized cognitive tests in com-
bination with subjective decline in any cognitive
domain were classified as SCD according to the
SCD-I framework, which requires self-experienced
cognitive decline unrelated to an acute event in any
cognitive domain, normal functions of daily living
(ADL-function), and performance within the normal
range on standardized cognitive tests [28]. In contrast,
cases classified as healthy controls had not experi-
enced cognitive decline. For the purpose of this study,
SCD participants were further classified as medical
help-seekers (HS, n = 67) or non-help-seekers (NHS,
n = 44). Participants recruited from GP referral were
automatically classified as HS (n = 46/67, 69%). In
addition, participants recruited from advertisement
who answered yes to having a prior history of seeking
help for SCD were also classified as HS (n = 21/67,
31%). Participants recruited from advertisement who
had not sought help for SCD were classified as NHS
(n = 44).
Participants
The DDI cohort comprises cases classified as
healthy controls, SCD, MCI, or dementia (n = 658).
For the present study, only cognitively normal healthy
controls and SCD cases with available CSF AD
biomarkers from the DDI cohort (n = 199) were
included. Our sample comprised cognitively nor-
mal healthy controls (n = 88), SCD-HS (n = 67), and
SCD-NHS (n = 44). Informant confirmation of SCD
was only available for a small subset of SCD cases
(n = 39/111, 35%), thus no statistical analyses were
performed using this variable. However, type of
SCD complaint (memory, language, orientation, or
attention/executive functions) was included in our
between-group analyses. An outline of the participant
inclusion process is depicted in Fig. 1. For description
of group demographics, see Table 1.
CSF collection and handling
Following DDI procedures as described previ-
ously [20], lumbar puncture was performed before
noon, CSF was collected in polypropylene tubes
(Thermo Nunc) and centrifuged within 4 h at 2000 g
for 10 min at room temperature. The supernatant
was transferred to new tubes and frozen at –80◦C
prior to analysis. All CSF samples were analyzed
at the Department of Interdisciplinary Laboratory
Medicine and Medical Biochemistry at Akershus
University Hospital, and samples from other DDI
sites were frozen before shipment to the laboratory.
Handling and analysis followed the BIOMARKAPD
SOPs [43]. Analyses were performed consecutively
as part of routine work-up, as described previously
[20, 44], and showed an optimal cut-off at CSF
A1–42 ≤708 for amyloid plaque pathology as com-
pared to a PET [18F]-flutemetamol uptake study [44].
Protein biomarker measurements
Commercial enzyme-linked immunosorbent
assays based on monoclonal antibodies were used
to measure CSF levels of the following protein
biomarkers: A1–42, t-tau, and p-tau were deter-
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Fig. 1. A total of n = 199 subjective cognitive decline (SCD) and controls from the Dementia Disease Initiation (DDI) cohort comprising n = 88
cognitively healthy controls, n = 67 SCD with a history of medical help seeking (SCD-HS) and n = 44 SCD non-help-seekers (SCD-NHS)
were included.
mined using Innotest A (1–42), Innotest h-Tau Ag,
and Innotest Phospho-Tau (181P) (Fujirebio, Ghent,
Belgium), respectively.
Statistical analysis
Examination of QQ-plots, histograms, and the
Shapiro-Wilks test of normality were used to assess
normality. For variables with normal distributions,
assessment of between group differences in CSF
biomarker levels, cognition, age, and years of edu-
cation were performed using one-way ANOVAs
with planned comparisons. Kruskal-Wallis test with
Dunn’s non-parametric pairwise post-hoc test was
used to assess group differences in variables with non-
normal distributions (CSF A1-42, CSF t-tau, CSF
t-tau, and MMSE). The dichotomous variable “sex”
and between-group distributions of SCD complaint
type were assessed using a chi square test. For sta-
tistically significant between-group differences using
one-way ANOVAs or Kruskal-Wallis tests, effect
sizes (eta squared, η2) are reported. Groups were
compared in the following manner: First, we com-
pared healthy controls to both the SCD-HS and
SCD-NHS groups. Then, SCD-HS group was com-
pared to SCD-NHS group. Lastly, we compared
the distribution of symptoms of depression with or
without the presence of amyloid plaques between
the SCD-HS and SCD-NHS groups using a chi
square test as well as observed numbers and per-
centages. This yielded four groups comprising cases
with amyloid plaques without symptoms of depres-
sion (A+Dep-), symptoms of depression without
amyloid plaques (A-Dep+), amyloid plaques and
symptoms of depression (A+Dep+), and lastly,
cases with neither amyloid plaques nor symptoms of
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Table 1
Between-group comparisons of CSF biomarkers, cognitive performance, demographics and depressive symptoms
Variable Groups F / χ2 / η2/ (p) ANOVA planned contrasts (p)
1. Controls 2. SCD-HS 3. SCD-NHS 1 versus 2 1 versus 3 2 versus 3
n = 88 n = 67 n = 44
Age
Mean (SD) 61.4 (9.4) 60.8 (8.3) 64.2 (9.9) F = 1.9, (n.s) n.s n.s n.s
Female
n (%) 48 (55%) 33 (49%) 17 (39%) χ2 = 2.8, (n.s) * * *
Years of education
Mean (SD) 14.0 (3.3) 13.6 (3.3) 13.5 (3.3) F = 0.6, (n.s) * * *
GDS 15
Mean (SD) 0.7 (1.1) 3.9 (3.0) 1.7 (2.0) F = 43.6, η2 = 0.31, (<0.0001) <0.0001 <0.05 <0.0001
MMSE
Median (IQR) 30 (1) 29 (1) 30 (2) χ2 = 0.3, (n.s) * * *
CERAD Learning T-score
Mean (SD) 52.9 (9.8) 47.0 (9.6) 53.4 (9.0) F = 8.8, η2 = 0.08, (<0.0001) <0.0001 n.s <0.001
CERAD Recall T-score
Mean (SD) 52.8 (7.8) 47.6 (8.9) 52.8 (9.0) F = 8.3, η2 = 0.08, (<0.001) <0.0001 n.s <0.01
TMT-A T-score
Mean (SD) 49.4 (9.0) 49.9 (8.4) 47.5 (9.7) F = 1.1, (n.s) * * *
TMT-B T-score
Mean (SD) 52.2 (7.6) 50.5 (8.7) 50.8 (7.8) F = 1.0, (n.s) * * *
COWAT T-score
Mean (SD) 51.7 (8.2) 51.8 (9.3) 51.9 (8.9) F = 1.0, (n.s) * * *
VOSP silhouettes
Mean (SD) 52.6 (9.0) 51.1 (11.0) 54.9 (9.7) F = 0.2, (n.s) * * *
CSF A1-42
Mean (SD) 1055 (230) 932 (310) 1022 (296) F = 3.9, η2 = 0.04, (<0.05) <0.01 n.s n.s
CSF t-tau
Mean (SD) 324 (152) 335 (210) 364 (181) F = 0.7, (n.s) n.s n.s n.s
CSF p-tau
Mean (SD) 53 (19) 57 (30) 59 (23) F = 1.0, (n.s) n.s n.s n.s
SCD Memory n (%) 53 (84%) 32 (80%) χ2 = 0.6, (n.s) * * *
SCD Executive functions n (%) 3 (5%) 3 (7%) χ2 = 0.3, (n.s) * * *
SCD Language n (%) 5 (8%) 10 (13%) χ2 = 0.5, (n.s) * * *
SCD Orientation n (%) 2 (3%) 0 (0%) χ2 = 1.3, (n.s) * * *
n, sample size; n.s., non-significant results; *No contrasts/post hoc tests performed; F, F-statistic; χ2, chi-square or Kruskal-Wallis statistic;
η2, eta-squared, p, p-value.
depression (A-Dep-). All analyses were performed
in the Statistical Package for Social Sciences (SPSS)
version 25.
Ethics
The Regional Medical Research Ethics committee
approved the study. All participants gave their written
informed consent before taking part in the study. All
further study conduct was in line with the guidelines
provided by the Helsinki declaration of 1964; revised
2013 and the Norwegian Health and Research act.
RESULTS
Group comparisons of cognitive performance
and demographics
Between-group comparisons of cognitive vari-
ables and demographics are shown in Table 1.
While the SCD-NHS group had similar cognitive
scores as the healthy controls, SCD-HS had signif-
icantly lower scores on both CERAD learning and
delayed memory recall as compared to both con-
trols (p < 0.0001; p < 0.0001) and SCD-NHS group
(p < 0.0001; p < 0.001). There was no significant dif-
ference in type of SCD cognitive complaint, age,
years of education, or sex distribution between the
groups.
Group comparisons of GDS-15 depressive
symptoms
Between-group comparisons of GDS-15 are shown
in Table 1.
Both SCD-HS (p < 0001) and SCD-NHS (<0.05)
groups reported higher levels of depressive symptoms
as compared to controls. However, SCD-HS group
reported more depressive symptoms than the SCD-
NHS group (p < 0.0001).
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Between-group CSF AD biomarkers comparisons
Between-group comparisons of CSF variables are
shown in Table 1.
While SCD-NHS had similar CSF A1-42 levels
as compared to controls, SCD-HS had lower CSF
A1-42 as compared to both SCD-NHS (p < 0.05) and
controls (p < 0.001).
We found no between-group differences in CSF
t-tau or p-tau levels.
Within-group distributions of amyloid plaques
and symptoms of depression
There were higher rates of A+Dep- cases (n = 18,
27%) within the SCD-HS group as compared to the
SCD-NHS group (A+Dep-, n = 7, 16%, p < 0.0001).
Moreover, we found higher rates of A-Dep+ cases
(n = 12, 18%, p < 0.0001) in the SCD-HS group as
compared to no cases within the SCD-NHS group.
No A+Dep+ cases were found in the SCD-HS group
and only one case within the SCD-NHS group was
A+Dep+ (see Table 2).
Within-group differences in cognitive
performance and demographics
In light of the results shown in the previous
section, we performed Kruskal-Wallis tests with Bon-
ferroni adjusted Dunn’s pairwise comparisons to
investigate potential differences in cognitive perfor-
mance and demographics between SCD help-seekers
with either amyloid plaques or symptoms of depres-
sion and cases with neither symptoms of depression
nor amyloid plaques (see Table 3). While help-
seekers with symptoms of depression were younger
(M = 55.8, SD = 8.4) compared to cases with amyloid
plaques (M = 64.5, SD = 8.3, p < 0.05), no significant
between-group differences in cognitive performance
or demographics were found.
Table 2
Frequencies of amyloid plaques and symptoms of depression in
SCD-HS and SCD-NHS
Groups SCD-HS SCD-NHS χ2 (p)
n (%) n (%)
A- Dep- 37 (55%) 36 (82%) χ2 = 73.0, p < 0.0001
A+ Dep- 18 (27%) 7 (16%) χ2 = 25.0, p < 0.0001
A- Dep+ 12 (18%) 0 (0%) *
A+ Dep+ 0 (0%) 1 (2%) *
p, p-value; n, sample size; χ2, chi-square test; A+/–, presence
or absence of amyloid plaque pathology (CSF A1-42 ≥ 708);
Dep+/–, presence or absence of symptoms of depression
(GDS ≥ 6). *No statistical tests performed.
DISCUSSION
The main finding of this study was that SCD cases
with self-reported history of medical help-seeking
had lower levels of CSF A1-42, weaker performance
on the CERAD word list memory test, and increased
levels of depressive symptoms compared to both SCD
non-help-seekers and controls. However, additional
analyses revealed that the SCD help-seeker group
comprised three subgroups: 1) subjects with symp-
toms of depression, 2) subjects with amyloid plaques,
and 3) subjects with neither amyloid plaques nor
symptoms of depression. Of note, none of the SCD
help-seekers had both amyloid plaques and symp-
toms of depression. Interestingly, all three subgroups
of SCD help-seekers showed equal memory perfor-
mance, regardless of amyloid status or symptoms of
depression.
While many studies have found recruitment source
differences in both AD biomarker prevalence and
cognitive performance in MCI [21, 24, 25], stud-
ies on SCD have been inconsistent [22, 24, 26, 27].
A recent meta-analysis found no difference in the
risk of progression of SCD patients recruited by
different means [4]. This is in line with a previ-
ous report from our group, showing no significant
differences in cognitive performance or demograph-
ics between memory-clinic referred and self-referred
SCD cases from the community [24]. Inconsistencies
between studies may partly be due to help-seeking
SCD patients not being referred for extensive
assessment at memory clinics by their GP. These
individuals may subsequently volunteer for research
participation.
Several studies have shown that SCD cases
recruited through memory clinics show increased
rates of pathological AD biomarkers [20, 26, 27].
In the present study, we found lower CSF A1-42 in
the SCD-HS group as compared to both SCD-NHS
and controls. Additional analyses confirmed that the
SCD-HS group had a higher rate of amyloid plaques
(n = 18, 27%) compared to the SCD-NHS group
(n = 8, 18%). The majority of these cases (n = 46,
69%) were indeed recruited from memory clinics,
which supports the idea of a recruitment bias when
including at-risk cases from memory clinics [23, 26,
27]. Moreover, we also found subtle deficits in mem-
ory performance in the SCD-HS group compared
to both SCD-NHS and controls. This is in contrast
to our previous study where no differences in cog-
nitive performance between memory-clinic referred
and self-referred SCD cases from the community
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Table 3
Comparisons of demographics and cognitive performance between SCD help-seekers with either amyloid plaques or symptoms of depression
and cases with neither amyloid plaques nor symptoms of depression
Variable Groups χ2 / η2/ (p) Bonferroni adjusted Dunn’s
pairwise comparisons (p)
1. SCD-HS 2. SCD-HS 3. SCD-HS 1 versus 2 1 versus 3 2 versus 3
A-Dep- A+Dep- A-Dep+
n = 37 n = 18 n = 12
Age
Mean (SD) 60.7 (7.6) 64.5 (8.3) 55.8 (8.4) χ2 = 7.7, η2 = 0.09, (<0.05) n.s n.s <0.05
Female
n (%) 21 (57%) 8 (44%) 4 (33%) χ2 = 2.2, (n.s) * * *
Years of education
Mean (SD) 13.8 (3.5) 13.5 (3.2) 12.8 (2.9) χ2 = 0.5, (n.s) * * *
MMSE
Median (IQR) 29 (2) 30 (2) 29 (3) χ2 = 0.4, (n.s) * * *
CERAD Learning T-score
Mean (SD) 47.4 (10.2) 48.8 (8.7) 43.2 (8.6) χ2 = 3.4, (n.s) * * *
CERAD Recall T-score
Mean (SD) 47.8 (9.2) 47.4 (9.3) 47.1 (7.5) χ2 = 0.9, (n.s) * * *
TMT-A T-score
Mean (SD) 48.9 (8.3) 58.9 (8.8) 48.5 (7.5) χ2 = 2.4, (n.s) * * *
TMT-B T-score
Mean (SD) 51.9 (9.4) 50.7 (6.7) 45.9 (7.8) χ2 = 3.3, (n.s) * * *
COWAT T-score
Mean (SD) 52.4 (8.8) 51.2 (10.1) 51.0 (10.5) χ2 = 0.2, (n.s) * * *
VOSP silhouettes
Mean (SD) 51.5 (13.0) 51.4 (8.1) 59.8 (9.2) χ2 = 0.9, (n.s) * * *
A+/–, presence or absence of amyloid plaque pathology (CSF A1-42 ≤708); Dep+/–, presence or absence of symptoms of depression
(GDS ≥ 6); n, sample size; n.s., non-significant results; *No contrasts/post hoc tests performed; χ2, chi-square or Kruskal-Wallis statistic;
η2, eta-squared, p, p-value. Pairwise comparisons are adjusted for multiple comparisons using Bonferroni correction of the p-values.
could be demonstrated [24]. These findings suggest
that help seeking status, not memory clinic recruit-
ment per se, may be a risk factor for early amyloid
deposition which could tie in with the subtle deficits
in memory performance observed in the SCD-HS
group. Moreover, we did not find differences in CSF
biomarkers or cognitive performance between SCD
NHS and controls, suggesting that the SCD-NHS
group has lower risk and may reflect higher rates of
benign SCD [16–18]. No differences between groups
were found in levels of CSF t-tau or p-tau. This is
perhaps not surprising, as increased levels of t-tau
and p-tau are associated with substantial formation
of neurofibrillary tangles and neuronal loss which
may happen downstream from amyloid deposition
and herald the onset of clinical cognitive impair-
ment at later stages [45]. It has been suggested
that weakening of memory performance is at first
related to A1-42 levels, and progressive loss of neu-
rons and the formation of neurofibrillary tangles is
associated with disease severity and progression to
dementia [46]. Indeed, several studies have suggested
that the presence of amyloid pathology in SCD is
the strongest predictor of future cognitive decline
[11–13].
Both SCD-HS and SCD-NHS groups had
increased levels of depressive symptoms compared
to controls. The increase in symptoms may reflect the
psychological strain of experiencing cognitive diffi-
culties regardless of brain pathology. However, levels
of depressive symptoms as measured by the GDS-
15 were significantly higher in SCD-HS. Additional
analyses revealed that this group indeed comprised
a high rate of individuals with above threshold
(GDS-15≥6) symptoms of depression (n = 12, 18%).
However, none of these individuals harbored amyloid
pathology, suggesting that symptoms of depression
may not be strongly associated with AD in its pre-
clinical phases and also that symptoms of depression
in these cases are not due to the strain of experiencing
incipient AD.
While memory performance has shown to predict
later cognitive decline and future dementia onset [47,
48], deficits in cognitive performance is also a core
feature in clinical depression [49]. Cognitive deficits
in depression have been reported within a number
886 R. Espenes et al. / Medical Help-Seeking Due to SCD
of cognitive domains including executive function-
ing, attention, learning, memory, and psychomotor
speed [50–52]. Interestingly, while we found poorer
memory function in help-seeking SCD cases as com-
pared to non-help-seekers, additional analyses could
not distinguish SCD help-seekers with symptoms of
depression from help-seekers with amyloid plaques
with regard to cognitive performance in neither mem-
ory domains nor other cognitive domains. However,
there are conflicting results regarding which domains
of cognition are selectively affected in clinical depres-
sion [53–57].
As most SCD cases are benign, or not caused
by degenerative brain disease [17], it has been sug-
gested that SCD may be associated with depression,
rather than preclinical AD [58, 59]. While it has
been reported that presentation of SCD may corre-
late with depression rather than objective cognitive
decline [60, 61], the link between SCD and depres-
sive symptoms has not been universally supported
[62, 63].
Nonetheless, it has been reported that prior his-
tory of depression is associated with increased risk
of developing AD [64]. Indeed, clinical depression
is associated with AD later in the disease trajec-
tory [65, 66], and an association between amyloid
pathology and late-life depression has been found
in several studies [67–70]. However, recent studies
have demonstrated that this may not be the case in
the preclinical phase of AD. Perin et al. [71] showed
that incidence of clinical depression, as determined
by the GDS-15, was not increased in cognitively
normal individuals with amyloid plaques. Similarly,
Donovan et al. [72] showed that an increased level
of depressive symptoms was not associated with the
presence of amyloid plaques in cognitively healthy
cases. These results tie in with our findings, as we
did not find an association between amyloid plaques
and symptoms of depression in SCD cases. How-
ever, this does not dismiss a relationship between
AD pathology and clinical depression as the disease
progresses.
Although clinical depression and preclinical AD
may not be linked, several studies have suggested
that subthreshold symptoms of depression and anxi-
ety may be manifestations of preclinical AD [73–75].
Subthreshold levels of depression could be related
to worry due to self-perceived reduction in cogni-
tion, rather than reflecting clinical depression, in
that awareness of SCD causes depressive symptoms
which explains increases in distress [76]. Several
studies have shown that worried individuals with
SCD have an increased risk of developing objective
cognitive decline [6, 28, 29, 77]. However, Chen, et
al. [62] recently showed that individuals with amyloid
plaques, self-reported memory difficulties or mem-
ory concerns and not depression or anxiety, were
associated with self-awareness of actual worsening
in memory function [62]. In our sample, memory
was the most frequent SCD complaint, regardless of
help-seeking status. This ties in with findings show-
ing that worry is associated with an increased risk
of dementia rather than the mere presence of mem-
ory complaints [77]. Taken together, this suggests
that specific concerns regarding cognition, not sub-
threshold levels of depression or anxiety, may confer
increased risk of clinical progression. These reports
are in accordance with our findings showing that
help-seeking due to SCD with amyloid plaques may
reflect worry or concerns due to a subtle deficit in
memory function which is unrelated to symptoms of
depression.
We also identified individuals with neither amy-
loid plaques nor symptoms of depression among the
help-seeking group with subtle memory deficits, per-
haps reflecting a different type of pathology such as
preclinical Lewy body dementia [78], earlier stages
of preclinical AD not yet identified using conven-
tional CSF biomarker cut-offs for amyloid pathology
(i.e., pre-plaque amyloid dysmetabolism) or per-
haps comprising of worried participants with normal
age-related memory decline without the presence
of neurodegenerative brain disease [79]. This find-
ing also points to a central limitation of our study,
which is confined to a cross sectional design and
information of progression is therefore lacking. A
longitudinal design is needed to assess whether help-
seeking SCD cases with amyloid plaques progress to
AD-type MCI or dementia, and if participants with-
out amyloid plaques with, or without symptoms of
depression will regress or progress with regards to
depressive symptoms, SCD, and cognitive perfor-
mance. Moreover, we did not include information
about whether help-seeking was caused by subjec-
tive worry due to SCD, or if individuals sought help
for other reasons, i.e., having a family history of
AD, or informant concern. Unfortunately, due to a
lack of available informant reports, this data was
not included in our analysis. It has been shown that
informant concern may be a better predictor than self-
concern of objective cognitive decline [80], and it has
been argued that many patients may not express their
concern to their GPs [81]. Consequently, non-help-
seeking SCD also includes cases with AD pathology,
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albeit with different reasons for not seeking
medical help.
Conclusions
Our findings shed light on the relationship between
depressive symptoms and preclinical AD, which may
inform researchers including at-risk cases for inter-
ventions studies, as well as GPs seeing cognitively
healthy, but worried patients with SCD. While our
results support the idea that individuals with SCD
seeking help may be at higher risk of AD, SCD
help-seekers also included younger individuals with
symptoms of depression without amyloid plaques as
well as individuals with neither symptoms of depres-
sion nor amyloid plaques. These subgroups could not
be distinguished based on performance on neuropsy-
chological tests, and longitudinal studies are needed
to ascertain the clinical progression of SCD help-
seekers with regards to the presence or absence of
symptoms of depression and amyloid plaques.
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